(精选)valente.课件教学课件.pptVIP

L’impiego di device nello scompenso cardiaco avanzato;Definition;Severe symptoms of HF (NYHA III or IV) Fluid retention and/or low cardiac output at rest Objective evidence of severe cardiac dysfunction: low LVEF ( 30%) and/or elevated filling pressures and/or elevated NT pro BNP levels Severe impairment of functional capacity: inability to exercise and/or 6-MWD distance 300m and/or peak VO2 12-14 ml/kg/min At least one hospitalisation in the past 6 months Presence of all the previous features despite optmal medical therapy unless it is poorly tolerated or controidicated and CRT if indicated ;OF Abouzzedine, MM Redfield Congest Heart Fail 2011;INTERMACS Heart Failure classification;Progress in Cardiovascular Diseases 54 (2011) 78-85;Progress in Cardiovascular Diseases 54 (2011) 78-85;Prevalence;Device nello scompenso cardiaco avanzato;Cardiac resincronizaton therapy;Length of support Short term: 24 h Medium term : 2 weeks Long term: 2 weeks Permanent Goals bridge to HTx bridge to recovery bridge to decision destination therapy;IABP;ECMO;ECMO VENO-ARTERIOSO ;Indicazioni ECMO in UTIC;Indicazioni ECMO in UTIC; ;5 pz;The study randomly assigned 129 pz with end-stage heart failure inelegible for cardiac transplantation to receive a left ventricular assist device (68 pz) or optimal medical management (61 pz). ;Comparison of Pulsatile flow and Continuous flow LVADs;P Khazanie, JG Rogers Congest Heart Fail 2011;;Patient Selection;Conclusions; Necessità di: Numero telefonico dedicato Equipe impianto ECMO H 24 Disponibilità posto letto dedicato;Costs